CD4 and neoplasm: Consistent with the results of Fig. 6a, OVA-specific CD8+ iTCM cells alone had some tumour-suppressive effects, however, combination with OVA-specific CD4+ iTSCM significantly improved the antitumour effects (Fig. 6c,d), and their combination induced remission in 24% of the mice (Fig. 6e).